Evaluating the role of human papillomavirus vaccine in cervical cancer prevention

Statistical Methods in Medical Research

Volumn 13, Issue 2, 2004, Pages 139-155

  Kang, Minhee ^a   Lagakos, Stephen W ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

CANCER GROWTH; CANCER RISK; CARCINOMA IN SITU; CLINICAL TRIAL; CONDYLOMA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; FEMALE; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; INFECTION RESISTANCE; REVIEW; STATISTICAL ANALYSIS; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

CLINICAL TRIALS; DISEASE PROGRESSION; DRUG EVALUATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 1642411120     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280204sm358ra     Document Type: Review

References (17)

1. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine 1998; 338: 423-28.
2. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of the National Cancer Institute 2000; 92: 464-74.
3. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. New England Journal of Medicine 1999; 341: 1633-39.
4. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002; 347: 1645-51.
5. Moscicki A-B, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E, Palefsky J. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. Journal of Pediatrics 1998; 132: 277-84.
6. Kay R. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 1986; 42: 855-65.
7. Gentleman RC, Lawless JF, Lindsey JC, Yan P. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Statistics in Medicine 1994; 13: 805-21.
8. Prentice RL. Surogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1998; 8: 431-40.
9. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Controlled Clinical Trials 2001; 22: 485-502.
10. Cox DR, Miller HD. The theory of stochastic processes. London: Chapman & Hall, 1977.
11. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau M-C, Désy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. Journal of Infectious Diseases 1999; 180: 1415-23.
12. Rida WN, Lawrence DN. Some statistical issues in HIV vaccine trials. Statistics in Medicine 1994; 13: 2155-77.
13. Dixon DO, Rida WN, Fast PE, Hoth DF. HIV vaccine trials: Some design issues including sample size calculation. Journal of Acquired Immune Deficiency Syndromes 1993; 6: 485-96.
14. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982; 1: 121-29.
15. Commenges D. Multi-state models in epidemiology. Lifetime Data Analysis 1999; 5: 315-27.
16. Hougaard P. Multi-state models: A review. Lifetime Data Analysis 1999; 5: 239-64.
17. Kalbfleisch JD, Lawless JF. The analysis of panel data under a Markov assumption. Journal of the American Statistical Association 1985; 80: 863-71.